Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance.
about
Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-AnalysisHigh rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?Isoniazid Mono-Resistant Tuberculosis: Impact on Treatment Outcome and Survival of Pulmonary Tuberculosis Patients in Southern Mexico 1995-2010Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosisUse of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosisResistance patterns among multidrug-resistant tuberculosis patients in greater metropolitan Mumbai: trends over timeAlarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, IndiaPrevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, PeruHigh levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India.Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, UgandaMycobacterium tuberculosis Beijing lineage favors the spread of multidrug-resistant tuberculosis in the Republic of Georgia.Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South AfricaDrug resistance of Mycobacterium tuberculosis in Malawi: a cross-sectional surveyThe growing problem of multidrug-resistant tuberculosis in North Korea.Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005-2010.A four-year nationwide molecular epidemiological study in Estonia: risk factors for tuberculosis transmission.Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysisMultidrug resistant tuberculosis in prisons located in former Soviet countries: A systematic review.Mixed-strain mycobacterium tuberculosis infections and the implications for tuberculosis treatment and controlHigh relapse rate in RNTCP: An increasing concern and time to intervene.High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova.Multi-drug resistant childhood tuberculosis.The Complex Relationship between Virulence and Antibiotic Resistance.Scenario Analysis for Programmatic Tuberculosis Control in Western Province, Papua New Guinea.Comparing different technologies for active TB case-finding among the homeless: a transmission-dynamic modelling study.Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000-2015.Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment
P2860
Q26781111-9F30B786-CB74-4A2F-B347-8A38A21C5A02Q28365057-C5C219DF-D724-4316-AB34-7349330E0B85Q28468519-CC6A3676-00B9-4AC2-9D96-8C7A0C49EF3CQ28471986-008F801A-2ECF-43E2-9A00-07D88C83AE9CQ28480576-4FB7D1E5-BCF0-4E6E-89B3-EBB785B7B9DCQ28543045-A080D751-CD89-4997-B553-E012BA45D695Q28543967-E000E2AD-302F-49DE-8246-AA9E03F0C739Q28551162-09B8F37C-61E4-4E45-9346-2465F210610DQ33475938-D735A5CD-12CF-432C-9769-B3AEEFB8FCEBQ33904830-FB731966-26F3-402D-B201-0E5D2E1EED7DQ34190370-2FFF5E1E-77A6-4780-BA09-E487F34361B8Q34216252-B9E3697A-9BE1-49C3-95BF-3C070EDD6DEBQ34460358-97D5F683-552E-4855-B839-BE8272D660E9Q34916373-F1D9987F-7235-401E-B833-B242F17328B6Q35673493-B47D98AB-F097-4896-80CB-154C6B1C2371Q35990670-CF4E36BD-43B8-4D88-A116-FB405C377B05Q36001543-A3F924B8-1460-46EE-A1D4-228664A06CD6Q36320130-0C6BC121-94F2-48BD-9DDB-71E4AE2B3A4FQ36361918-6A17CF6C-0271-4F56-8E66-6B5EFCCDFC60Q36817959-B3038543-43AA-4DAF-94FD-4B9F25307FE6Q37733149-9F97CA3E-A3A6-4E38-9AA1-F343796AD5DFQ37824823-6A2518D8-4DD5-4376-BB18-3F5F4062DDDCQ39096546-2B03E310-FCEB-410F-9DA4-450A7AB5F1D9Q39751186-3D5399CD-2311-4281-96BD-64D377DF6D2EQ48181298-70E73B28-37A9-4B73-957F-D556E5EA1063Q50317039-38C01E00-CCDF-4923-9A1A-D658B25433D0Q58790087-D74BA0CE-663B-483F-BEE3-BC151D7B88C0
P2860
Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Risk of acquired drug resistan ...... igh levels of drug resistance.
@en
Risk of acquired drug resistan ...... igh levels of drug resistance.
@nl
type
label
Risk of acquired drug resistan ...... igh levels of drug resistance.
@en
Risk of acquired drug resistan ...... igh levels of drug resistance.
@nl
prefLabel
Risk of acquired drug resistan ...... igh levels of drug resistance.
@en
Risk of acquired drug resistan ...... igh levels of drug resistance.
@nl
P2093
P2860
P356
P1476
Risk of acquired drug resistan ...... igh levels of drug resistance.
@en
P2093
Daribay Doshetov
Gabit Ismailov
Juan Daniel Orozco
Lucie Blok
Sabine Rüsch-Gerdes
Stefan Niemann
Yared Kebede
P2860
P304
P356
10.1086/517536
P407
P50
P577
2007-04-24T00:00:00Z